Menu

Claire Mazumdar Is on the 2026 TIME100 Next India
📰

Claire Mazumdar Is on the 2026 TIME100 Next India

TIME·Alice Park·about 14 hours ago
#leN5iBcV
#time#mazumdar#immune#system#cancer
Reading 0:00
15s threshold

Harnessing the immune system is becoming an important part of treating cancer, and potentially even a requirement for curing some cases. Claire Mazumdar co-founded Bicara to exploit this possibility, and the company’s lead immunotherapy product is preparing to start late-stage human studies in people with head and neck cancer. The antibody binds to two different molecules, including one that suppresses the ability of the immune system to target tumors, thus giving the drug a better chance of being effective.

With studies on the experimental treatment so far positive, Mazumdar announced in September that she will move into a new role as adviser and vice chair of the board of directors. It’s only one stop on her journey, though: Mazumdar has already been named as the potential successor to her aunt’s Indian biopharma company Biocon, which has a market capitalization of around $6 billion.